Redirecting to deep profile of Pawan Bhusari at Abiogenesis Clinpharm...
Click here to continueBelow are the verified contact details to help you connect directly:
Email: paw*****@abi******.com
Mobile: 81385*****
Estimated Net Worth: ₹0 – ₹500+ Cr (approx. $0 – $60M)
- Pawan Bhusari co-founded Abiogenesis Clinpharm Private Limited in November 2014, taking on the role of CEO and leading the company in the clinical research field.
- Prior to founding Abiogenesis, Pawan served as Associate Director of Clinical Operations at Sristek Clinical Research Solutions Limited from April 2014 to October 2014, where responsibilities included overseeing clinical trial processes.
- Pawan contributed as Senior Manager of Clinical Operations at Sristek Clinical Research Solutions Limited from April 2008 until March 2014, playing a vital role in managing clinical project teams and ensuring operational excellence.
- Before positions at Sristek, Pawan worked as Manager of Clinical Operations at Makrocare Clinical Research Pvt Ltd from September 2007 to March 2008, where experience in project management and operational oversight was gained.
- From December 2006 to August 2007, Pawan served as Deputy Manager of Clinical Development at Dr. Reddy’s Laboratories Ltd, where involvement in drug development processes advanced expertise in clinical research.
- Pawan’s career began as Assistant Manager of Clinical Research at Shantha Biotechnics Ltd from April 2001 to November 2006, building foundational knowledge in clinical trials and research methodologies.
- Prior to entering the clinical research domain, Pawan worked as a Business Officer at Zydus Cadila Ltd from September 1998 to March 2001, where business development acumen was developed.
- Throughout the career trajectory, Pawan faced and overcame challenges associated with leading diverse teams and managing complex clinical trial operations, demonstrating resilience and adaptability in various roles within the pharmaceutical industry.
- Abiogenesis Clinpharm, under Pawan's leadership, has made significant strides in enhancing clinical trial methodologies and delivering robust research services, positioning itself as a noteworthy player in the clinical research sector.